Amygdala is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [1]
The amygdala (from Greek amygdale, meaning "almond") is a bilateral, almond-shaped nuclear complex located deep within the medial temporal lobes, anterior to the [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- and inferior to the uncus. It is a critical hub for emotional processing, fear conditioning, social cognition, and the integration of sensory information with emotional valence. The amygdala has gained particular importance in neurodegenerative disease research because it is among the earliest brain structures affected by tau] pathology] in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, displays selective vulnerability to [α-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX-- aggregation in [Lewy body dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia--TEMP--/diseases)--FIX-- and [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, and undergoes profound atrophy in behavioral variant [Frontotemporal Dementia (bvFTD)[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX-- 1(https://link.springer.com/article/10.1186/s13024-019-0333-5) 2(https://link.springer.com/article/10.1186/s13024-022-00533-z). [2]
The amygdala is not a single homogeneous structure but a heterogeneous complex of approximately 13 nuclei grouped into three major subdivisions. These subdivisions differ in cytoarchitecture, connectivity, and physiological function, which helps explain why neurodegenerative diseases can produce selective patterns of emotional and autonomic dysfunction depending on the nuclei involved.[9][11]
Classically, the nuclei are organized into basolateral, centromedial, and cortical/medial groups. The basolateral system functions as a high-bandwidth sensory-associative module
with dense reciprocal inputs from [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, [thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus--TEMP--/brain-regions)--FIX--, and [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--, while centromedial nuclei provide descending autonomic and behavioral output through projections to
[hypothalamus[/brain-regions/[hypothalamus[/brain-regions/[hypothalamus[/brain-regions/[hypothalamus--TEMP--/brain-regions)--FIX-- and [brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem--TEMP--/brain-regions)--FIX--. Cortical/medial divisions and the extended amygdala interface with olfactory and sustained threat-processing networks, supporting state-dependent
salience assignment.[11][12]
This subdivision-level architecture is clinically relevant because neurodegenerative proteinopathies can involve these circuits unevenly, producing dissociable phenotypes in fear learning, social-emotional judgment, autonomic responsivity, and behavioral inhibition.[10][15]
The basolateral complex—comprising the lateral (LA), basal (B), and accessory basal (AB) nuclei—is the largest subdivision and serves as the primary sensory input hub. The lateral
nucleus receives convergent inputs from the [thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus[/brain-regions/[thalamus--TEMP--/brain-regions)--FIX--, sensory [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--, and [prefrontal cortex[/brain-regions/[prefrontal-cortex[/brain-regions/[prefrontal-cortex[/brain-regions/[prefrontal-cortex--TEMP--/brain-regions)--FIX--. It is the critical site for fear conditioning, where associations
between conditioned stimuli and aversive outcomes are formed and stored. The basal nucleus integrates these signals and projects to the central nucleus for motor output and to the
prefrontal [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- for conscious emotional appraisal.[11][12]
The BLA is composed primarily of glutamatergic projection [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- (~80%) and GABAergic interneurons (~20%), giving it a [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX---like cytoarchitecture distinct from the
subcortical organization of the central nucleus. This cortical-like composition may explain its particular vulnerability to certain neurodegenerative proteinopathies, including
selective socioemotional-network injury in [Frontotemporal Dementia (bvFTD)[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--.[10][13]
The central (CeA) and medial (MeA) nuclei form the major output station of the amygdala. The CeA projects to the hypothalamus, brainstem autonomic nuclei, and periaqueductal gray, mediating the physiological expressions of fear and anxiety (tachycardia, freezing, stress hormone release). The CeA has a striatal-like organization with predominantly GABAergic medium spiny [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, functionally connecting the amygdala's emotional processing to the body's autonomic and neuroendocrine stress responses.[9]
The cortical nuclei and the bed nucleus of the stria terminalis (BNST, sometimes called the "extended amygdala") are involved in processing olfactory information, reproductive behavior, and sustained anxiety states. The extended amygdala has gained recognition for its role in chronic stress responses and anxiety disorders, which are common comorbidities in neurodegenerative diseases.
The amygdala integrates signals from all major neurotransmitter systems:
Overall, convergent glutamatergic and modulatory monoaminergic signaling shapes excitation-inhibition balance in basolateral circuits, a substrate that is frequently disrupted in neurodegenerative syndromes with anxiety, apathy, and altered salience processing.[11][12]
This rich neurochemical diversity means that the amygdala is affected by the degeneration of multiple ascending neurotransmitter systems that occurs across different neurodegenerative diseases.[5][15]
The amygdala is one of the earliest sites of neurofibrillary tangle (NFT) formation in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--. In the Braak staging system, tau pathology] reaches the amygdala at stage III—before the neocortex is significantly affected—and continues to accumulate through stages IV–VI. The corticomedial and basolateral nuclei are preferentially affected, with NFT density eventually rivaling or exceeding that of the [entorhinal cortex[/brain-regions/[entorhinal-cortex[/brain-regions/[entorhinal-cortex[/brain-regions/[entorhinal-cortex--TEMP--/brain-regions)--FIX-- and [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- in advanced disease 1(https://link.springer.com/article/10.1186/s13024-019-0333-5) 2(https://link.springer.com/article/10.1186/s13024-022-00533-z).
[Amyloid-β[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- plaques are found throughout the amygdala, though their distribution is more diffuse than in the neocortex. [Amyloid] [PET imaging[/diagnostics/[pet-imaging[/diagnostics/[pet-imaging[/diagnostics/[pet-imaging--TEMP--/diagnostics)--FIX-- studies have demonstrated early amygdalar amyloid deposition in preclinical [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, and the amygdala is among the first subcortical structures to reach amyloid positivity on PET scans 3(https://www.ncbi.nlm.nih.gov/books/NBK499922/).
A distinctive pathological finding in a subset of [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- cases is amygdala-predominant Lewy body pathology, where [α-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX-- aggregates are essentially confined to the amygdala without the widespread cortical distribution seen in [Lewy body dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia--TEMP--/diseases)--FIX--. This "amygdala-predominant" pattern is found in approximately 60% of familial Alzheimer's cases with [PSEN1[/genes/[psen1[/genes/[psen1[/genes/[psen1--TEMP--/genes)--FIX-- or [PSEN2[/genes/[psen2[/genes/[psen2[/genes/[psen2--TEMP--/genes)--FIX-- mutations and up to 40% of sporadic AD cases at autopsy, suggesting that the amygdalar microenvironment is particularly permissive for α in the context of concurrent AD pathology 4(https://www.nature.com/articles/s41531-024-00684-4).
Amygdala atrophy and dysfunction in Alzheimer's Disease correlate with several neuropsychiatric symptoms that profoundly impact quality of life:
The amygdala undergoes severe and early degeneration in behavioral variant [Frontotemporal Dementia (bvFTD)[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX--, with volume loss often exceeding 30–40% by the time of clinical diagnosis. The right amygdala is frequently more affected than the left, consistent with the right-hemisphere predominance of social-emotional processing. This profound amygdalar atrophy accounts for many of the signature behavioral features of bvFTD:
In primary tauopathies including [Progressive Supranuclear Palsy (PSP)[/diseases/[progressive-supranuclear-palsy[/diseases/[progressive-supranuclear-palsy[/diseases/[progressive-supranuclear-palsy--TEMP--/diseases)--FIX--, [Corticobasal Degeneration (CBD)[/diseases/[corticobasal-degeneration[/diseases/[corticobasal-degeneration[/diseases/[corticobasal-degeneration--TEMP--/diseases)--FIX--, and Pick's disease (a subtype of FTD), tau pathology in the amygdala shows distinct morphological and isoform-specific patterns. Pick bodies (3R tau, globose tangles (4R tau in PSP), and astrocytic plaques (4R tau in CBD) each preferentially affect different amygdalar subnuclei, reflecting the selective vulnerability of specific neuronal populations to different tau strains.[15]
In the Braak staging of [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, Lewy body pathology reaches the amygdala at stage IV, following the ascending pattern from the brainstem through the [locus coeruleus[/brain-regions/[locus-coeruleus[/brain-regions/[locus-coeruleus[/brain-regions/[locus-coeruleus--TEMP--/brain-regions)--FIX-- and [substantia nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra--TEMP--/brain-regions)--FIX--. However, the amygdala may be affected even earlier in some cases, and the density of α in the amygdala often exceeds that of other limbic structures. In [Lewy body dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia[/diseases/[lewy-body-dementia--TEMP--/diseases)--FIX--, the amygdala is consistently and heavily involved, with Lewy neurites and Lewy bodies distributed throughout both the basolateral and centromedial subdivisions 4(https://www.nature.com/articles/s41531-024-00684-4).
Amygdala dysfunction in [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- contributes substantially to the non-motor symptom burden:
In [CTE[/mechanisms/[cte[/mechanisms/[cte[/mechanisms/[cte--TEMP--/mechanisms)--FIX--, tau pathology] shows a predilection for the superficial cortical layers and perivascular regions, but the amygdala is also affected—particularly at advanced stages (McKee stage III–IV). Amygdala involvement may contribute to the emotional dysregulation, aggression, and impulsivity described in CTE 6(https://jnm.snmjournals.org/content/64/2/274).
While [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX-- primarily affects the striatum, amygdala pathology has been documented and may account for the emotional recognition deficits (particularly disgust and fear) that are early features of HD, sometimes preceding motor symptoms 6(https://jnm.snmjournals.org/content/64/2/274).
In [prion diseases[/diseases/[prion-diseases[/diseases/[prion-diseases[/diseases/[prion-diseases--TEMP--/diseases)--FIX-- including [Creutzfeldt-Jakob disease[/diseases/[creutzfeldt-jakob[/diseases/[creutzfeldt-jakob[/diseases/[creutzfeldt-jakob--TEMP--/diseases)--FIX-- and [fatal familial insomnia (FFI)[/diseases/[fatal-familial-insomnia[/diseases/[fatal-familial-insomnia[/diseases/[fatal-familial-insomnia--TEMP--/diseases)--FIX--, the amygdala and thalamus are among the preferentially affected structures, with PrPSc deposition and spongiform change contributing to the psychiatric and autonomic symptoms that characterize these disorders.
Volumetric MRI reliably detects amygdala atrophy in neurodegenerative diseases. Automated segmentation tools (FreeSurfer, FSL FIRST) allow measurement of amygdala volume in clinical research, and amygdala atrophy rates can distinguish between different dementia subtypes:
Task-based fMRI studies demonstrate altered amygdala reactivity in neurodegenerative diseases. In AD, amygdala responses to emotional faces are diminished, while in bvFTD, both reduced reactivity and loss of amygdala–prefrontal connectivity are observed. Resting-state fMRI reveals disrupted amygdala–default mode network connectivity in prodromal AD 1(https://link.springer.com/article/10.1186/s13024-019-0333-5).
[Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX-- [PET] tracers (18F-flortaucipir) demonstrate early amygdala uptake in Alzheimer's Disease, and amygdalar tau PET signal correlates with neuropsychiatric symptom severity better than hippocampal tau burden. FDG-PET reveals amygdala hypometabolism in both AD and bvFTD, with distinct patterns helping in differential diagnosis 6(https://jnm.snmjournals.org/content/64/2/274).
Amygdala volume, connectivity, and metabolism are emerging as important biomarkers for several applications:
The study of Amygdala has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
This section links to atlas resources relevant to this brain region.